Abstract
Multinational clinical trials to investigate drug therapy under a common protocol are becoming increasingly common in drug development. In most cases multinational trials are set up to enable—in an acceptable time period — the conduct of a study that requires specific conditions like availability of patients having a rare disease or a cer tain infrastructure or expertise in investigation al centers. Experience at Bayer shows that study preparation and evaluation/documentation need substantially longer than for multicenter trials in one country. The problems with such trials are manifold and can be found in differences in medical practice, regulations, culture, and in organiz ing the trial. If a multinational trial cannot be avoided it should be restricted to coun tries and centers with similar medical practice. From drafting the protocol unto the publication the teamwork needs firm coordination and leadership in order to com plete the study successfully.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
